VA
CSTL icon

Valmark Advisers’s Castle Biosciences CSTL Stock Holding History

Valmark Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,269
Closed -$320K – 447
2022
Q3 		$320K Sell
12,269
-697
-5% -$19.5K 0.01% 339
2022
Q2 		$285K Buy
12,966
+3,534
+37% +$82.1K 0.01% 356
2022
Q1 		$423K Buy
9,432
+148
+2% +$6.12K 0.01% 325
2021
Q4 		$398K Buy
9,284
+260
+3% +$13.6K 0.01% 307
2021
Q3 		$600K Buy
9,024
+229
+3% +$16.1K 0.01% 256
2021
Q2 		$645K Buy
8,795
+351
+4% +$23.2K 0.01% 251
2021
Q1 		$578K Sell
8,444
-3,236
-28% -$243K 0.01% 253
2020
Q4 		$784K Buy
+11,680
New +$633K 0.02% 201

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Valmark Advisers's CSTL Position: Q4 2022 in Review

Valmark Advisers sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 12,269 shares — an estimated $320K sold.

Valmark Advisers first reported a position in CSTL in Q4 2020 and held it in 8 quarters. The position peaked at $784K in Q4 2020. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Valmark Advisers reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Valmark Advisers sold 12,269 Castle Biosciences shares in Q4 2022, an estimated $320K.
  • Valmark Advisers first reported a position in Castle Biosciences in Q4 2020 and held it in 8 quarters.
  • Valmark Advisers's Castle Biosciences position peaked at $784K in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Valmark Advisers's 13F filing for Q4 2022, filed 7 Feb 2023.